This section shows a summary for the selected study (COSU identifier) or publication (COSP identifier). Studies may have been performed by the Sanger Institute Cancer Genome Project, or imported from the ICGC/TCGA. You can see more information on the help pages.
- Reference
- Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients.
- Paper ID
- COSP45523
- Authors
- Affiliation
- Molecular Microbiology & Immunology and Norris Comprehensive Cancer Center, Beijing Friendship Hospital, Capital Medical University, No.95 Yong-an Road, Xi-Cheng District, Beijing, 100050, China.
- Journal
-
Bioscience reports, 2018
ISSN: 1573-4935
PMID: 29914973 (view at PubMed or Europe PMC) - Abstract
- Characterization, diagnosis, and treatment of colorectal cancers (CRC) are difficult due to limited biopsy information, impracticality of repeated biopsies, and cancer biomarker fallibility. Circulating tumor DNA (ctDNA) has recently been investigated as a non-invasive way to gain representative gene mutations in tumors, in addition to monitoring disease progression and response to treatment. We analyzed ctDNA mutations and concentrations in 47 early- and late-stage CRC patients using a targeted sequencing approach using a panel that covers 50 cancer-related genes. ctDNA mutations in 37 genes ( were identified in 93.6% of the patients (n=47). The results showed that <i>TP53</i> , <i>PIK3CA</i> , <i>APC</i> , and <i>EGFR</i> were the most frequently mutated genes. Stage IV patients had significantly higher ctDNA concentration than stage I patients, and increased ctDNA concentration correlated with increased tumor size. Additionally, ctDNA detection was found to be a greater predictor of disease when compared to five known commonly used tumor biomarkers. Our study supports the use of ctDNA as a liquid biopsy to gain clinical tumor information that may facilitate early diagnosis and treatment and improve CRC patient prognosis.
- Paper Status
- Listed